On February 28, 2013, “Yanbin Fuzheng Capsule” clinical efficacy observation study of treating chronic hepatitis B and cirrhosis of hepatitis B”, which was jointly completed by the First People’s Hospital of Lanzhou City and Lanzhou Yanbin Biotechnology Limited Liability Company, passed the scientific and technological achievements appraisal organized by the Science and Technology Department of Gansu Province, and experts attending the meeting listened to the report of the subject group and reviewed the relevant information. The experts listened to the report of the group, reviewed the relevant information, after questioning and discussion, formed the following opinions. Yanbin Fuzheng Capsule is an empirical formula composed of Poria, Safflower, Lotus Seed, Jujube Kernel, Papaya, Peach Kernel, Ophiopogon and other traditional Chinese medicines. This project retrospectively summarized the efficacy of Yanbin Fuzheng Capsule in the treatment of chronic hepatitis B and liver cirrhosis, and compared it with the adefovir treatment group. The results of the study showed that the use of “Yanbin Fuzheng Capsule” alone could reduce the levels of HBsAg, HBeAg, and HBV-DNA load, similar to the control group; in terms of the improvement of liver function, the therapeutic group also had a better therapeutic effect; the therapeutic group had a better effect on the alleviation of the clinical symptoms of cirrhosis, the improvement of the indicators of liver fibrosis, and the imaging indexes of liver and spleen, all of which were excellent in terms of alleviation of clinical symptoms, improvement of liver fibrosis indexes, and improvement of liver and spleen imaging indexes. The clinical symptoms, liver fibrosis indexes and liver and spleen imaging indexes of the treatment group were better than those of the control group (P0.01), indicating that the therapeutic efficacy of YANBIN FUZHEN CAPSULE in the treatment of chronic hepatitis B and cirrhosis of hepatitis B is certain, and it is worthy of further research. The study is closely integrated with clinical practice, highlights the characteristics of traditional Chinese medicine, has a reasonable design, informative data and credible conclusions. The research results have reached the leading level of similar research in China. Agree to pass the appraisal of scientific and technological achievements. There are about 120 million HBsAg carriers in China, of which about 20-30 million are patients with chronic hepatitis B. Many patients improve after antiviral treatment, and HBVDNA and HBeAg are negative, but because the current antiviral drugs can not eradicate HBsAg, so it is easy to cause the disease to recur, and the repeated treatments cause great pressure on the patients psychologically, physically, and financially, and rural patients and urban low-income patients can not afford to pay the high cost of treatment. Patients in rural areas and low-income patients in urban areas are unable to afford the high medical costs, which leads to the delay of the disease and easy to develop into cirrhosis or liver cancer. HBsAg and liver cirrhosis is a difficult problem in the current clinical treatment, the observation of the clinical effect of traditional Chinese medicine, we found that traditional Chinese medicine has a good effect on the removal of hepatitis B virus, the technical route is to use the immunomodulatory function of traditional Chinese medicine to reduce the immune tolerance of patients with hepatitis B, and the use of immune cells to remove the hepatitis B virus, the effect of which is similar to that of western drug adefovir; in the treatment of cirrhosis (decompensated or compensated) traditional Chinese medicine Yanbin Fuyi, the treatment of cirrhosis (compensated or compensated), the effect is similar to the western drug Adefovir. ) The effect of traditional Chinese medicine Yanbin Fuzheng Capsule is better than western medicine, and it is effective in improving the clinical symptoms, liver fibrosis index, hepatomegaly, splenomegaly, and in improving the clinical symptoms of patients with liver cirrhosis. This is the first time in China that Chinese medicine is now found to have anti-hepatitis B virus and can reduce HBsAg.